<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness (i.e., a diminished ability of <z:chebi fb="105" ids="17234">glucose</z:chebi> per se to facilitate its own metabolism), increased gluconeogenesis, and endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> release are, together with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and beta-cell abnormalities, established features of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>To explore aspects of the pathophysiology behind type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we assessed in a group of healthy people prone to develop type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 23), namely first-degree relatives of type 2 diabetic patients (FDR), 1) endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> release and fasting gluconeogenesis measured using the 2H2O technique and 2) <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness </plain></SENT>
<SENT sid="2" pm="."><plain>The FDR group was insulin resistant when compared with an age-, sex-, and BMI-matched control group without a family history of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 14) (M value, clamp: 6.07 +/- 0.48 vs. 8.06 +/- 0.69 mg x kg(-1) lean body weight (lbw) x min(-1); P = 0.02) </plain></SENT>
<SENT sid="3" pm="."><plain>Fasting rates of gluconeogenesis (1.28 +/- 0.06 vs. 1.41 +/- 0.07 mg x kg(-1) lbw x min(-1); FDR vs. control subjects, P = 0.18) did not differ in the two groups and accounted for 53 +/- 2 and 60 +/- 3% of total endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> release </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> effectiveness was examined using a combined somatostatin and insulin infusion (0.17 vs. 0.14 mU x kg(-1) x min(-1), FDR vs. control subjects), the latter replacing serum insulin at near baseline levels </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, a 360-min labeled <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion was given to simulate a prandial <z:chebi fb="105" ids="17234">glucose</z:chebi> profile </plain></SENT>
<SENT sid="6" pm="."><plain>After <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion, the integrated plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> response above baseline (1,817 +/- 94 vs. 1,789 +/- 141 mmol/l per 6 h), the ability of <z:chebi fb="105" ids="17234">glucose</z:chebi> to simulate its own uptake (1.50 +/- 0.13 vs. 1.32 +/- 0.16 ml x kg(-1) lbw x min(-1)), and the ability of <z:chebi fb="105" ids="17234">glucose</z:chebi> per se to suppress endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> release did not differ between the FDR and control group </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, in contrast to overt type 2 diabetic patients, healthy people at high risk of developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are characterized by <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness at near-basal insulinemia and <z:mpath ids='MPATH_458'>normal</z:mpath> fasting rates of gluconeogenesis </plain></SENT>
</text></document>